Delaware | 001-36783 | 20-1450200 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
2130 W. Holcombe Blvd., Ste. 800 Houston, TX | 77030 | |||
(Address of principal executive offices) | (Zip Code) |
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Exhibit No. | Description | |
99.1 |
Bellicum Pharmaceuticals, Inc. | ||||||
Dated: August 7, 2018 | By: | /s/ Alan A. Musso | ||||
Alan A. Musso | ||||||
Chief Financial Officer and Treasurer | ||||||
Indication | Pediatric Acute Myeloid Leukemia (n=38) | Primary Immune Deficiencies (n=59) |
Median Follow-Up (Months) | 15.5 (1.2-38.0) | 17.6 (1.1-41.2) |
Relapse-Free / Disease-Free Survival | 89.3% | 87.6% |
Overall Survival | 94.5% | 87.6% |
Acute GvHD (Grade III-IV) | 0.0% | 1.8% |
Chronic GvHD | 3.0% | 3.0% |
GvHD Response Rate to Rimiducid | 80% | 83% |
BELLICUM PHARMACEUTICALS, INC. | ||||||||||||||||
Unaudited Condensed Balance Sheets | ||||||||||||||||
(in thousands) | ||||||||||||||||
June 30, | December 31, | |||||||||||||||
2018 | 2017 | |||||||||||||||
Current Assets: | ||||||||||||||||
Cash and cash equivalents | $ | 73,458 | $ | 38,839 | ||||||||||||
Investment securities, available-for-sale, short-term | 55,923 | 60,057 | ||||||||||||||
Receivables and other current assets | 2,889 | 2,754 | ||||||||||||||
Non-Current Assets: | ||||||||||||||||
Investment securities, available-for-sale, long-term | — | 1,368 | ||||||||||||||
Property and equipment, net | 23,854 | 25,942 | ||||||||||||||
Restricted cash | 5,902 | 6,190 | ||||||||||||||
Other assets | 396 | 378 | ||||||||||||||
Total assets | $ | 162,422 | $ | 135,528 | ||||||||||||
Current Liabilities: | ||||||||||||||||
Accounts payable and other accrued liabilities | 8,899 | 9,679 | ||||||||||||||
Other current liabilities | 4,029 | 2,477 | ||||||||||||||
Long-Term Liabilities: | ||||||||||||||||
Other liabilities, net of current portion | 36,956 | 38,724 | ||||||||||||||
Total Stockholders' Equity | 112,538 | 84,648 | ||||||||||||||
Total liabilities and stockholders' equity | $ | 162,422 | $ | 135,528 | ||||||||||||
BELLICUM PHARMACEUTICALS, INC. | ||||||||||||||||
Unaudited Condensed Statements of Operations | ||||||||||||||||
(in thousands, except share and per share amounts) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2018 | 2017 | 2018 | 2017 | |||||||||||||
Grant Revenues | $ | 362 | $ | — | $ | 516 | $ | 128 | ||||||||
Operating Expenses: | ||||||||||||||||
Research and development | 18,412 | 17,959 | 34,948 | 33,254 | ||||||||||||
License fees | 150 | 343 | 180 | 698 | ||||||||||||
General and administrative | 5,367 | 5,486 | 11,059 | 11,413 | ||||||||||||
Total operating expenses | 23,929 | 23,788 | 46,187 | 45,365 | ||||||||||||
Operating loss | (23,567 | ) | (23,788 | ) | (45,671 | ) | (45,237 | ) | ||||||||
Interest expense, net of interest income | (608 | ) | (669 | ) | (1,344 | ) | (1,193 | ) | ||||||||
Net loss attributable to common shareholders | $ | (24,175 | ) | $ | (24,457 | ) | $ | (47,015 | ) | $ | (46,430 | ) | ||||
Net loss per share attributable to common shareholders, basic and diluted | $ | (0.60 | ) | $ | (0.74 | ) | $ | (1.27 | ) | $ | (1.54 | ) | ||||
Weighted-average common shares outstanding, basic and diluted | 40,605,953 | 33,074,463 | 37,050,949 | 30,201,116 | ||||||||||||
(_$&E>'[=ONRZI>QVRG\
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M.\93E1-+*D>$R!E AW#(W#O^I5%% !1110 4444 %%NZVBCS=>U^%+N[=^[*6&V(=L1A1
MCKGJ?<-5\(:%KM@+#4M%T[4+$+L%K=6L
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end